Human Reproduction Update, Vol.9, No.4 pp.387-396, 2003
© European Society of Human Reproduction and Embryology 2003; all rights reserved
Gynaecology |
Progestogens for endometriosis: forward to the past
1 Clinica Ostetrica e Ginecologica I, Istituto ‘Luigi Mangiagalli’, Università di Milano, 2 Clinica Ostetrica e Ginecologica III, Ospedale San Paolo, Università di Milano and 3 Clinica Ostetrica e Ginecologica II, Istituto ‘Luigi Mangiagalli’, Università di Milano, Milano, Italy 4 Clinica Ostetrica e Ginecologica I, Istituto ‘Luigi Mangiagalli’, Università di Milano, Via Commenda, 12 – 20122 Milano, Italy
To whom correspondence should be addressed at: Paolo Vercellini, Clinica Ostetrica e Ginecologica I, Istituto ‘Luigi Mangiagalli’, Università di Milano, Via Commenda, 12 – 20122 Milano, Italy. e-mail: paolo.vercellini{at}unimi.it
Abstract
We performed a MEDLINE and EMBASE search to identify all studies published in the last decade in the English language literature on the use of progestogens for the treatment of endometriosis. Our aim was to clarify the biological rationale for treatment and define the drugs that can be used with their doses, routes of administration, efficacy and tolerability. Progestogens may prevent implantation and growth of regurgitated endometrium inhibiting expression of matrix metalloproteinases and angiogenesis, and they have several anti-inflammatory in-vitro and in-vivo effects that may reduce the inflammatory state generated by the metabolic activity of the ectopic endometrium, and the consequent immune response. Oral contraceptives increase the abnormally low apoptotic activity of the endometrium of women with endometriosis. Moreover, anovulation, decidualization, amenorrhoea and the establishment of a steady estrogen–progestogen milieu contribute to disease quiescence. Progestogens are effective in the control of pain symptoms in approximately three out of four women with endometriosis. Their effect does not seem to be inferior to that of other drugs used for the disease. Different compounds can be administered by the oral, intramuscular, subcutaneous, intravaginal or intrauterine route, each with specific advantages or disadvantages. Medical treatment plays a role in the therapeutic strategy when administered over a prolonged period of time. Given their good tolerability, minor metabolic effects and low cost, progestogens must therefore be considered drugs of choice and are currently the only safe and economic alternative to surgery. However, their contraceptive effectiveness limits their use to women who do not wish to have children in the short term.
Key words: endometriosis / oral contraceptives / pelvic pain / progestogens
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Yuan, Y. Huang, H. Wu, Z. Teng, J. Zhang, and X. Xin Induction of a local pseudo-pregnancy via levonorgestrel-loaded microspheres for the treatment of endometriosis in a rabbit model Hum. Reprod., November 7, 2009; (2009) dep386v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Monckedieck, C. Sannecke, B. Husen, M. Kumbartski, R. Kimmig, M. Totsch, E. Winterhager, and R. Grummer Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model Mol. Hum. Reprod., October 1, 2009; 15(10): 633 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vercellini, P. G. Crosignani, E. Somigliana, N. Berlanda, G. Barbara, and L. Fedele Medical treatment for rectovaginal endometriosis: what is the evidence? Hum. Reprod., October 1, 2009; 24(10): 2504 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tsuno, K. Nasu, A. Yuge, H. Matsumoto, M. Nishida, and H. Narahara Decidualization Attenuates the Contractility of Eutopic and Ectopic Endometrial Stromal Cells: Implications for Hormone Therapy of Endometriosis J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2516 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vercellini, P.G. Crosignani, A. Abbiati, E. Somigliana, P. Vigano, and L. Fedele The effect of surgery for symptomatic endometriosis: the other side of the story Hum. Reprod. Update, March 1, 2009; 15(2): 177 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Bruner-Tran, Z. Zhang, E. Eisenberg, R. C. Winneker, and K. G. Osteen Down-Regulation of Endometrial Matrix Metalloproteinase-3 and -7 Expression in Vitro and Therapeutic Regression of Experimental Endometriosis in Vivo by a Novel Nonsteroidal Progesterone Receptor Agonist, Tanaproget J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1554 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Crosignani, D. Olive, A. Bergqvist, and A. Luciano Advances in the management of endometriosis: an update for clinicians Hum. Reprod. Update, March 1, 2006; 12(2): 179 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.G. Crosignani, A. Luciano, A. Ray, and A. Bergqvist Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain Hum. Reprod., January 1, 2006; 21(1): 248 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ESHRE Capri Workshop Group Noncontraceptive health benefits of combined oral contraception Hum. Reprod. Update, September 1, 2005; 11(5): 513 - 525. [Abstract] [Full Text] [PDF]
|
|